Pseudophakic cystoid macular edema
- PMID: 12759847
Pseudophakic cystoid macular edema
Abstract
Cystoid macular edema (CME) following cataract surgery has been recognized for over 50 years as an important cause of suboptimal post-operative vision. The incidence of CME varies widely, but is likely in the range of 1-2% using modern cataract extraction techniques. The diagnosis of CME can generally be made on clinical examination with evidence of perifoveal cystic spaces and can be confirmed with use of fluorescein angiography to document the classic petaloid pattern of leakage mainly into the outer retina. Leak from perifoveal vessels is induced by inflammatory mediators and results in intraretinal fluid accumulation and corresponding decrease in retinal function. The risk factors most associated with CME; rupture of posterior capsule, vitreous loss, iris incarceration, use of iris fixated lenses, active uveitis and diabetes, may all increase the potency of these mediators and exacerbate post-operative CME. The treatment of CME remains controversial but generally starts with conservative observation in isolated angiographic cases and progresses through topical non-steroidal anti-inflammatory agents (NSAIDs), topical steroids, peri-ocular steroids, systemic steroids and surgical intervention in refractory cases. Even more controversial is the role of NSAID prophylaxis peri-operatively in preventing clinical CME. Though the data is tantalizing in the short term, there is little to support the long-term benefit of such prophylaxis with respect to visual outcomes.
Similar articles
-
Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment.J Cataract Refract Surg. 2007 Sep;33(9):1550-8. doi: 10.1016/j.jcrs.2007.05.013. J Cataract Refract Surg. 2007. PMID: 17720069
-
Pseudophakic cystoid macular edema.Ophthalmologica. 2012;227(2):61-7. doi: 10.1159/000331277. Epub 2011 Sep 15. Ophthalmologica. 2012. PMID: 21921587 Review.
-
Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension.Ophthalmology. 1999 May;106(5):1024-9. doi: 10.1016/S0161-6420(99)00528-X. Ophthalmology. 1999. PMID: 10328408
-
Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction.Ophthalmology. 1999 Sep;106(9):1656-9. doi: 10.1016/S0161-6420(99)90366-4. Ophthalmology. 1999. PMID: 10485530 Clinical Trial.
-
Cystoid macular edema.Optom Clin. 1996;5(1):111-30. Optom Clin. 1996. PMID: 8963073 Review.
Cited by
-
Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%.Clin Ophthalmol. 2009;3:147-54. doi: 10.2147/opth.s4684. Epub 2009 Jun 2. Clin Ophthalmol. 2009. PMID: 19668559 Free PMC article.
-
Retinal phototoxicity in a novel murine model of intraocular lens implantation.Mol Vis. 2009 Dec 12;15:2751-61. Mol Vis. 2009. PMID: 20019883 Free PMC article.
-
Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema.Retina. 2011 Feb;31(2):284-9. doi: 10.1097/IAE.0b013e3181f049a8. Retina. 2011. PMID: 20948459 Free PMC article. Clinical Trial.
-
Müller cells as players in retinal degeneration and edema.Graefes Arch Clin Exp Ophthalmol. 2007 May;245(5):627-36. doi: 10.1007/s00417-006-0516-y. Epub 2007 Jan 12. Graefes Arch Clin Exp Ophthalmol. 2007. PMID: 17219109 Review.
-
Effect of nepafenac on the foveal profile of glaucomatous patients undergoing phacoemulsification.Int Ophthalmol. 2017 Oct;37(5):1147-1153. doi: 10.1007/s10792-016-0381-6. Epub 2016 Oct 22. Int Ophthalmol. 2017. PMID: 27771823